secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001193125-21-237729
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotech Q2 2021 GAAP net loss $5.1M vs prior-year profit; NERLYNX flat at $48.9M
--------------------------------------------------------------------------------

- GAAP net loss of $5.1M ($0.13 loss/share) vs net income of $3.4M in Q2 2020.
- Non-GAAP adjusted net income $13.1M ($0.32/share) vs $14.0M ($0.36/share) in Q2 2020.
- NERLYNX net revenue $48.9M, essentially flat vs $48.8M in Q2 2020.
- Cash & securities $108.9M at June 30, 2021, up from $93.4M at Dec 31, 2020.
- Received label expansion for NERLYNX dose escalation; SUMMIT top-line data expected Q4 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000119312521237729/0001193125-21-237729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000119312521237729/d212533d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-237729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer